Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
Journal of Pharmacy and Bioallied Sciences · 2023-07 · 15 (3) · 101-106
DOI: 10.4103/jpbs.jpbs_313_23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Bioallied Sciences, online erschienen am 15.08.2023. Verfasst von Hany A Al-Hussaniy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dr Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A BSTRACT Background: Clinical pharmacogenetics is a rapidly growing field that focuses on the study of genetic variations and their impact on drug metabolism, efficacy, and safety. Angiotensin II receptor blockers (ARBs) are commonly used to treat hypertension in Iraq but not all patients respond equally to these drugs.
Aim
This article aims to review the current evidence on the clinical pharmacogenetics of ARBs in Iraq and its implications for personalized medicine. Materials and Methods: We conducted a literature review of studies on the genetic variations that affect the response to ARBs in Iraq. We also reviewed the prevalence of these genetic variants in the Iraqi population and discussed the potential clinical implications for personalized medicine.
Results
The most studied genetic variations associated with ARB response in Iraq are the angiotensin-converting enzyme gene insertion/deletion polymorphism and the angiotensin II type 1 receptor gene A1166C polymorphism. The angiotensin-converting enzyme gene insertion/deletion polymorphism is associated with variability in response to ARBs, while the angiotensin II type 1 receptor A1166C polymorphism is associated with an increased risk of cardiovascular events in patients treated with ARBs. The prevalence of these genetic variants in the Iraqi population varies widely depending on the region and ethnic group.
Conclusion
The clinical pharmacogenetics of ARBs in Iraq suggests that pharmacogenetic testing could improve the selection and dosing of ARBs in Iraqi patients, leading to better patient outcomes and cost-effective healthcare.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dr Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq.
- Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.
- Bilad Alrafidain University College, Baqubah, Iraq.
- Department of Pharmacy, Al-Mahmoudiya General Hospital, Baghdad, Iraq.
- Department of Pharmacy, Al-Manara College for Medical Sciences, Amarah, Iraq.
- Department of Clinical Pharmacy, College of Pharmacy/University of Karbala, Iraq.
Zitieren
APA
Al-Hussaniy, H. A., Hassan, A. F., Oraibi, A. I., Al-Juhaishi, A. M. R., Naji, F. A., & Al-Tameemi, Z. S. (2023). Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq. Journal of Pharmacy and Bioallied Sciences, 15(3), 101-106. https://doi.org/10.4103/jpbs.jpbs_313_23
Vancouver
Al-Hussaniy HA, Hassan AF, Oraibi AI, Al-Juhaishi AMR, Naji FA, Al-Tameemi ZS. Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq. Journal of Pharmacy and Bioallied Sciences. 2023;15(3):101-106. doi:10.4103/jpbs.jpbs_313_23
BibTeX
@article{AlHussaniy2023,
author = {Al-Hussaniy, Hany A and Hassan, Alaa F and Oraibi, Amjad I and Al-Juhaishi, Atheer M R and Naji, Fatima A and Al-Tameemi, Zahraa S},
title = {Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq},
journal = {Journal of Pharmacy and Bioallied Sciences},
year = {2023},
volume = {15},
number = {3},
pages = {101--106},
doi = {10.4103/jpbs.jpbs_313_23}
}
EUVIMED